

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/OUTCOME/2018-19

Date: 13th November, 2018

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting.

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2018 as **Annexure-A** and
- b) Limited Review Report on the Un-Audited Financial Results as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- c) Cessation of Mr. Shri Prakash from the post of Whole time director of the Company.
- d) Cessation of Ms. Usha Pande from the post of Independent Director of the Company.
- e) Appointment of Ms. Sumita Dwivedi as an Additional Director in an Independent Category of the Company.

The meeting of the Board of Directors commenced on 11:00 am and concluded at 12.30 p.m.


The Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2018, as approved by the Board, will also be available on the Company's website at www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS- 44157



Independent Auditor's Review Report on Standalone Quarterly Financial Results

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43,
Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of **Medicamen Biotech Limited** for the quarter and half year ended 30th September, 2018 being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants


Rai Qimat & Associates
Partner
(Membership Number: 080857)

Place: New Delhi
Date: 13.11.2018


MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

Standalone Un-audited Financial Results for the Quarter and Half Year Ended 30th September 2018							
PART I		Rupees in Lacs (Except per Share data)					
	Particulars	Quarter Ended			For Half year ended		Year Ended
		3 Months Ended 30/09/2018	Preceding 3 Months Ended 30/06/2018	Corresponding 3 Months Ended 30/09/2017	30th Sep 2018	30th Sep 2017	Year Ended 31/03/2018
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net Sales/Income from operations (Net of excise duty)	3,248.82	3,276.34	2,790.66	6,525.16	5,391.35	11,150.72
	(b) Other Income	180.54	116.29	77.91	296.83	110.51	188.79
	(c) Total Revenue	3,429.36	3,392.63	2,868.57	6,821.99	5,501.86	11,339.51
2	Expenses						
	a) Cost of Material Consumed	2,049.14	1,934.20	1,621.26	3,983.34	3,250.03	6,878.24
	b) Purchase of Stock-in-Trade	-	-	0.05	-	0.05	0.05
	c) Changes in inventory of Finished Goods and Work in Progress	106.68	262.45	46.43	369.13	(4.92)	(113.07)
	d) Employees Benefits Expenses	236.99	216.79	261.54	453.78	474.43	905.30
	e) Finance Cost	35.11	35.77	61.34	70.88	115.41	240.81
	f) Depreciation and Amortisation Expenses	48.42	47.70	51.52	96.12	99.58	205.79
	g) Other expenses	442.05	441.73	490.11	883.78	917.60	1,832.38
	Total Expenses	2,918.39	2,938.64	2,532.25	5,857.03	4,852.18	9,949.51
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	510.97	453.99	336.32	964.96	649.68	1,390.00
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	510.97	453.99	336.32	964.96	649.68	1,390.00
6	Tax Expenses						
	Current Year	159.70	133.71	68.57	293.41	132.46	401.78
	Deferred Tax Liability	(4.71)	(1.92)	(0.13)	(6.63)	(1.26)	(23.05)
	Total Tax Expenses	154.99	131.79	68.44	286.78	131.20	378.73
7	Net Profit/Loss for the period (5 - 6)	355.98	322.20	267.88	678.18	518.48	1,011.27
8	Other Comprehensive Income						
	Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-
	Total Comprehensive income Net of Tax	355.98	322.20	267.88	678.18	518.48	1,011.27
9	Total Comprehensive income for the Period (7 + 8)	355.98	322.20	267.88	678.18	518.48	1,011.27
10	Paid-up equity share capital (Rs.10/- per share)	1,170.00	1,170.00	1,107.00	1,170.00	1,107.00	1,170.00
11	Earning Per Share (Rs.)						
	(a) Basic	3.05	2.75	2.42	5.80	4.68	9.03
	(b) Diluted	3.05	2.75	2.42	5.80	4.68	9.03

NOTES :

- 1 The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 13th, Nov, 2018.
- 2 The figures are regrouped in previous year also, wherever considered necessary.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 Auditor's Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors
Medicamen Biotech Limited


(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 13.11.2018

MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
STATEMENT OF ASSETS & LIABILITIES

Particulars	As at 30.09.2018 Un-audited	As at 31.03.2018 Audited
ASSETS		
Non-current assets		
Property, plant and Equipment	2,450.31	2,501.87
Intangible assets	31.92	31.69
Capital work-in-progress	254.93	27.86
Financial Assets		
Loans and advances	58.30	56.81
Other Non- current assets	38.26	38.26
Total Non-current Assets	2,833.71	2,656.49
Current assets		
Inventories	1,321.03	1,423.42
Financial Assets		
Current investments	-	7.00
Trade receivables	5,679.21	3,842.38
Cash and Bank Balances	1,230.15	2,266.48
Loans and advances	1,070.98	1,295.95
Other current assets	246.25	263.34
Total current Assets	9,547.61	9,098.57
Total Assets	12,381.33	11,755.06
EQUITY AND LIABILITIES		
Shareholders' Fund		
Equity share capital	1,170.00	1,170.00
Other Equity	6,968.97	6,290.79
Total Equity	8,138.97	7,460.79
LIABILITIES		
Non-current Liabilities		
Financial Liabilities		
Borrowings	7.95	14.18
Deferred Tax liabilities (Net)	34.72	41.36
Provisions	118.43	117.92
Total Non-current Liabilities	161.10	173.46
Current Liabilities		
Financial Liabilities		
Borrowings	306.35	1,424.45
Trade payables	3,191.35	2,180.00
Other current liabilities	290.14	86.60
Provisions	293.41	429.76
	4,081.25	4,120.81
TOTAL- EQUITY AND LIABILITIES	12,381.33	11,755.06

For & on behalf of Board of Directors
Medicamen Biotech Limited

(Rahul Bishnoi)
Chairman

Place : Delhi
Dated : 13.11.2018